CliffBio
small molecule

GRAFAPEX

TREOSULFAN

Loss of exclusivityJanuary 2032FDA regulatory exclusivity expiry
CompanyMedexus Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameGRAFAPEX
Active ingredientTREOSULFAN
Strength5GM/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJanuary 2025
Marketing statusRX

Listed patents

PatentExpiresType
7199162October 2026use U-4142

Regulatory exclusivity

CodeExpires
ODE-513January 2032
ODE-514January 2032
NCEJanuary 2030

More from Medexus Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

GRAFAPEX patent cliff — loss of exclusivity January 2032 | CliffBio